Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

Compared with sunitinib, cabozantinib improves overall response rates (ORR) and progression-free survival (PFS) among treatment-naive patients with advanced renal cell carcinoma (RCC) across all subgroups, according to research being presented at the 2018 Genitourinary Cancers Symposium in San Francisco, California.¹

Findings from the phase 2 CABOSUN study (ClinicalTrials.gov Identifier: NCT01835158) showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with intermediate- to poor-risk advanced RCC.

For this subgroup analysis of 157 patients in CABOSUN, researchers stratified patients by factors including age, sex, baseline function, and MET expression, as well as by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria and the presence of bone metastases.

Cabozantinib improved PFS in all subgroups vs sunitinib. The ORR was also higher among patients treated with cabozantinib vs sunitinib, with the greatest benefit observed in patients who were MET-positive (34% in the cabozantinib arm vs 10% in the sunitinib arm).

Median PFS was worse in both treatment arms in patients with an ECOG score 1 or 2 or who had bone metastases.

The authors concluded that “[cabozantinib] was associated with improved PFS and ORR compared with [sunitinib] in previously untreated [patients] with advanced RCC irrespective of baseline characteristics.”

Read more of Cancer Therapy Advisor‘s coverage of the 2018 Genitourinary Cancers Symposium by visiting the conference page.

Reference

1. George DJ, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial. Oral presentation at: 2018 Genitourinary Cancers Symposium; February 8-10, 2018; San Francisco, CA.